Securities Code: 300869 Bond Code: 123151 Securities Abbreviation: Kangtai Medical Bond Abbreviation: Kangyi Convertible Bond Announcement No.: 2026-018 Kangtai Medical System (Qinhuangdao) Co., Ltd. Announcement of Resolutions of the 27th Meeting of the Fourth Board of Directors
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, without false records, misleading statements, or major omissions.
I. Convening of the Board Meeting
The notice for the 27th meeting of the Fourth Board of Directors of Kangtai Medical System (Qinhuangdao) Co., Ltd. (hereinafter referred to as the "Company") was sent to all directors via email on April 14, 2026. The meeting was held on-site in the Company's conference room on April 24, 2026. The meeting was convened and presided over by Mr. Hu Kun, Chairman of the Company. There were 5 directors who should have attended, and 5 directors actually attended. Senior management personnel of the Company were present at the meeting. The convening, holding, and voting of this meeting complied with the provisions of the "Company Law of the People's Republic of China" and the "Articles of Association of Kangtai Medical System (Qinhuangdao) Co., Ltd." (hereinafter referred to as the "Articles of Association"). The meeting was legal and valid.
II. Deliberation of the Board Meeting
- Approval of the Proposal on the Company's 2025 Annual Report and its Summary
After deliberation, the "2025 Annual Report" and its summary compiled and audited by the Board of Directors comply with the regulations of laws, administrative regulations, the China Securities Regulatory Commission, and the Shenzhen Stock Exchange. The report's content is true, accurate, and complete, reflecting the actual operating situation of the Company in 2025 without any false records, misleading statements, or major omissions. The Company's 2025 financial status was audited by Deloitte Touche Tohmatsu (Special General Partnership), which issued a standard unqualified opinion on the "Financial Statements and Audit Report." The report issued by Deloitte Touche Tohmatsu (Special General Partnership) truthfully, objectively, accurately, and fairly reflects the Company's actual situation in 2025, with no false or erroneous records, and no omissions.
The Audit Committee of the Company's Board of Directors has reviewed and approved this proposal.
The full content can be found in the "2025 Annual Report," "2025 Annual Report Summary," and "2025 Audit Report" published by the Company on the same day on the Juchao Information Network (www.cninfo.com.cn), the designated information disclosure website of the China Securities Regulatory Commission for the ChiNext market.
Voting Results: 5 votes in favor; 0 votes against; 0 abstentions. This proposal was approved.
This proposal needs to be submitted to the shareholders' meeting for review.
- Approval of the Proposal on the Company's 2025 Board of Directors Work Report
Based on the Company's work in 2025 and its annual operating performance, the Board of Directors organized the compilation of the "2025 Board of Directors Work Report." The independent directors of the Company submitted their individual duty reports for 2025 and will present their reports at the 2025 shareholders' meeting.
The Board of Directors, based on the "Independent Directors' Self-Assessment Report on Independence" issued by the independent directors, evaluated the independence of the current independent directors and issued the "Board of Directors' Special Opinion on the Independence of Independent Directors."
The full content can be found in the "2025 Board of Directors Work Report," "Independent Directors' Duty Reports for 2025," and "Board of Directors' Special Opinion on the Independence of Independent Directors" published by the Company on the same day on the Juchao Information Network (www.cninfo.com.cn).